Abstract: A morphinan derivative represented by the following general formula (I) (in the formula, R1 represents hydrogen, C1-6 alkyl, cycloalkylalkyl (the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms), aralkyl (the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms) and the like, R2 represents hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, aralkyl (the aryl moiety has 6 to 10 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms) and the like, R3, R4 and R5 represent hydrogen, hydroxy, carbamoyl, C1-6 alkoxy, C6-10 aryloxy and the like, R6a, R6b, R7, R8, R9, and R10 represent hydrogen and the like, X represents O or CH2, and Y represents C?O, SO2, an atomic bond and the like), or an acid addition salt thereof is used as an analgesic.

Abstract: The present invention describes an oil-in-water emulsion composition for wet-wipes delivering an improved body cleansing performance while providing a gentle and smooth feeling to the user.

Abstract: A consumer product comprises silane-modified oil comprising a hydrocarbon chain selected from the group consisting of: a saturated oil, an unsaturated oil, and mixtures thereof; and at least one hydrolysable silyl group covalently bonded to the hydrocarbon chain. The silane-modified oil is substantially stripped of substantially stripped of reagents prior to formulating into the consumer products, such that the silane-modified oil comprises less than about 10%, preferably less than about 5%, preferably less than about 1%, preferably less than about 0.1%, by weight of said silane-modified oil, of residual reagent comprising silicon.

Abstract: Disclosed herein is a novel rinsing agent, which may be suitable for use in surgical, and, in particular, ophthalmological procedures. The rinsing agent may by employed to remove emulsified oil droplets from the eye cavity. Also disclosed is a method for effectively removing emulsified silicone oil droplets remaining in the eye cavity after ophthalmological procedures using the disclosed rinsing agent in order to prevent the development of long-term complications associated with the emulsified oil droplets.

Abstract: The present invention is directed to silicon-containing fumaric acid esters of the Formulae I-IV. The silicon-containing fumaric acid esters of Formulae I-IV are useful in transplantation medicine and for the treatment of autoimmune diseases and autoimmune-related diseases.

Abstract: The present invention provides a composition comprising a combination of components A) and B), wherein component A) is a compound of formula (I) and the component (B) is a further fungicide, insecticide or herbicide.

Abstract: Disclosed herein are compositions comprising, in a cosmetically acceptable medium, a silicone material comprising concave and/or annular particles; hydrophobic silica aerogel particles; fillers chosen from platelet type fillers and silica particles other than hydrophobic silica aerogel particles; a fatty substance chosen from fatty alcohols and fatty acids; an emulsifying agent and a thickening agent, wherein the silica material, hydrophobic silica aerogel particles and fillers are present in a total amount of greater than 4% by weight, based on the total weight of the composition. Also disclosed herein is a process for reducing the visibility of imperfections on skin, comprising applying the composition onto the skin.

Abstract: The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and/or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2?-trimethylsilyl)ethyl]-20(S) camptothecin) in an amount sufficient to provide a therapeutic benefit. The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed. Methods for the administration of Karenitecin to increase Progression Free Survival (PFS) are also disclosed and claimed herein.

Abstract: The use of isoquinolones for preparing drugs, including novel isoquinolones as well as their synthesis method. In particular, isoquinolone derivatives used in the treatment of pathological angiogenesis, and more particularly of cancer.

Abstract: The invention relates to a cosmetic composition, in particular a composition for making up and/or caring for keratin materials, preferably a nail makeup, comprising the compound of chemical formula (I) below: (I) in which: m represents an integer equal to 0 or 1; n represents an integer between 2 and 8; R1 represents a group (C1-C20)alkyl or an aryl group, or alternatively, when m is equal to 0, R1 may also represent a carbonyl; R2 and R3 represent an ethoxy group or a group (C1-C20)alkyl, optionally substituted with an amino group; Y represents a polyurea or a polyurethane or alternatively a hydrocarbon-based group comprising from 2 to 100 carbon atoms. The invention also relates to a cosmetic process, in particular a makeup or hair shaping process, preferably a process for making up keratin materials, in particular the nails and/or the hair, characterized in that it comprises at least one step which consists in applying a cosmetic composition as above defined to keratin materials.

Abstract: The invention provides an article for use with an animal, particularly a domesticated animal, comprising an antimicrobial agent and a polymer, wherein the antimicrobial agent is a quaternary ammonium compound. More specifically, the invention provides articles, such as grooming tools, for equestrian use which are capable of preventing the spread of diseases such as strangles, ringworm and diseases associated with Mycotoxins such as Fusarium.

Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.

Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein W is O or S; V is a direct bond or NR3; Q is or CR6aR6b, O, NR7, C?N—O—R7 or C(?O); Y is —C(R5)?N—O—(CR8aR8b)p—X—(CR9aR9b)q—SiR10aR10bR10c; or a phenyl ring substituted as defined in the disclosure; or Z; and R1, R2, R3, R4, R5, R6a, R6b, R7, R8a, R8b, R9a, R9b, R10a, R10b, R10c, Z, p and q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

Abstract: Metallocene compounds and pharmaceutical compositions containing these metallocene compounds are disclosed and described. Methods of treating cancer employing such metallocene compounds and pharmaceutical compositions also are provided.

Abstract: The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

Abstract: The present invention relates to a cosmetic or dermatological composition of sol/gel type for making up and/or caring for keratin materials characterized in that it comprises the product resulting from the reaction: (a) of at least one alkoxysilane monomer or oligomer of formula (I) R1xSi(OR2)(4-x) or of formula (II) [R1y (OR2)z SiO ((4-?-?)]? in which R1 represents, independently, a nucleophilic group other than a hydroxyl, or a (Ci-C2o)alkyl group, R2 represents, independently, a (Ci-Cio)alkyl group, and (b) of an amount of water corresponding to a number of moles of water, determined according to the following equation: X?(llAlkoxysilanes×llbAlkoxy groups)/nH2o with nH2o=Number of moles of water, nAikoxysiianes=Number of moles of alkoxysilane compounds, nbAikoxy groups=Weighted mean of the number of alkoxysilane groups per alkoxysilane compound, and X is a number greater than 2. It also relates to an associated cosmetic process and an associated kit for coating keratin materials.

Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein Q, A, R1, R2, R3 and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for treating helminth infections comprising administration to an animal a parasiticidally effective amount of a compound or a composition of the invention.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: The invention provides a family of fluorescent compounds. The compounds are substituted silaxanthenium compounds that can be chemically linked to one or more biomolecules, such as a protein, nucleic acid, and therapeutic small molecule. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications. The dyes are particularly useful for in vitro, in vivo and ex vivo imaging applications.

Abstract: A method for treating cancer that includes administering a pharmaceutically effective amount of a composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents a 5- to 10-membered heteroaryl group, or a C6-10 aryl group; R1 and R2 independently represent H, OH, X, CN, NO2, a C1-4 haloalkyl group, a C1-6 alkyl group, or the like <R1 and R2 together form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group>; R3 represents H, a C1-5 alkyl group, a C6-10 aryl group, a C1-5 alkyl group, or a C1-4 haloalkyl group; and R4 represents H, X, a C1-3 alkyl group, a C1-4 haloalkyl group, OH, CN, NO2, or the like.

Abstract: The present invention relates to fungicidal N-[(trisubstitutedsilyl)methyl]carboxamide or its thiocarboxamide derivative, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.

Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

Abstract: Quaternary ammonium materials may be immobilized onto a metal oxide nanoparticle to provide a fixed-quat nanoparticle material. A particular example uses a silicon alkoxide as a silicon source material to provide a fixed-quat SiNP/NG material composition through either acidic or basic hydrolysis of the silicon alkoxide material. Particular materials may be characterized spectroscopically to ensure that the desirable materials are properly bound. Specific applications of fixed-quat SiNP/NC material compositions in accordance with the embodiments include, but are not limited to agricultural biocide applications and tobacco smoke selective filtration applications.

Abstract: This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.

Abstract: A novel saccharide siloxane copolymer has improved stability in the presence of water as compared to certain previously known saccharide siloxanes. The saccharide siloxane copolymer is useful in personal care compositions.

Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, Q, and G are defined herein.

Abstract: The present invention relates to compositions including anhydrous compositions which include a dimethicone crosspolymer and/or dimethicone elastomer gum and one or more skin care products which may include retinoic acid, retinoic acid derivatives, retinal, retinol and/or retinyl esters, and methods of making, storing, and using such compositions.

Abstract: Described herein, at least in part, are methods of modulating oncogenic fusion proteins.

Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.

Abstract: The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.

Abstract: Silylated nitrones and methods of detecting and/or superoxide using silylated nitrones are disclosed herein.

Abstract: Methods and compositions for the treatment of pediculosis comprising: between 1 and 20% (w/w) isopropyl myristate; between 1 and 20% (w/w) silicone oil; and at least 20% (w/w) water.

Abstract: PROBLEM There are provided a composition for controlling plant diseases and a method for controlling plant diseases having excellent control effect for plant diseases. SOLUTION A composition for controlling plant diseases comprising, as active ingredients, a compound represented by formula (1), wherein X1 represents a methyl group, a difluoromethyl group or an ethyl group; X2 represents a methoxy group or a methylamino group; and X3 represents a phenyl group, a 2-methylphenyl group or a 2,5-dimethylphenyl group, and at least one azole compound selected from the group consisting of bromuconazole, cyproconazole, difenoconazole, fenbuconazole, fluquinconazole, hexaconazole, imibenconazole, ipconazole, myclobutanil, prothioconazole, simeconazole, tetraconazole, triticonazole and metconazole.

Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R1, R2, R3, Q, and G are defined herein.

Abstract: The invention relates to a process for capturing one or more carbonyl compounds B resulting from the reaction between one or more compounds constituting sebum and ozone on the surface of a material or in a material, characterized in that one or more compounds A having one or more nucleophilic functions FA forming in situ on the surface of said material or in said material a layer capturing said compound(s) B is (are) applied to the surface of said material. The invention also relates to the cosmetic use of one or more compounds A having one or more nucleophilic functions FA capable of reacting with one or more carbonyl compounds B resulting from the reaction between one or more compounds constituting sebum and ozone, as a soothing agent, said compound(s) with nucleophilic functions(s) being intended for preventing and/or treating discomforting reactions of keratin materials induced by the carbonyl compounds B.

Abstract: The present invention relates to novel heterocyclic alkanol derivatives, to processes for these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

Abstract: A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay. The modified release may be provided by (a) a high melt temperature, water-insoluble wax or waxy substance, (b) a low viscosity hydrophilic polymer such a hydroxypropyl methylcellulose, (c) a reverse enteric coating, or combinations thereof. The benzonatate may be in an adsorbate with a silico or silicate or in a complex with a weak acidic ion exchange resin complex.

Abstract: A foam medical patch is provided including a foam substrate having integrated therein an antimicrobial material comprising a silane quaternary ammonium salt. The antimicrobial material is substantially free from arsenic, silver, tin, heavy metals and polychlorinated phenols. The silane quaternary ammonium salt includes 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride.

Abstract: The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.

Abstract: Provided is a process for forming a dissolvable fiber, the process including (a) producing an extrudate from a twin screw extruder; and (b) forming the extrudate into the dissolvable fiber. The dissolvable fiber includes (i) from about 10% to about 60% of one or more anionic surfactants; (ii) from about 10% to about 50% of one or more water soluble polymers; (iii) from about 1% to about 30% of one or more plasticizers; and (iv) from about 0.01% to about 30% water. The one or more anionic surfactants have a Krafft point of less than about 30° C. The dissolvable fiber has an average diameter of from about 20 microns to about 1,000 microns.

Abstract: 3-Alkenyl-6-halo-4-aminopicolinic acids and their derivatives are potent herbicides demonstrating a broad spectrum of weed control.

Abstract: Heterocyclylpyri(mi)dinylpyrazole of the formula (I) in which R1 to R5, X1, U, Q, W, Y, n, a, b have the meanings given in the description, and agrochemically active salts, to their use and to methods and compositions for controlling phytopathogenic harmful fungi in and/or on plants or in and/or on seed of plants and for reducing mycotoxins in plants and parts of the plants, to processes for preparing such compounds and compositions and treated seed and also to their use for controlling phytopathogenic harmful fungi in agriculture, horticulture, forestry, in animal husbandry, in the protection of materials, in the domestic and hygiene field and for the reduction of mycotoxins in plants and parts of the plants

Abstract: A touch screen and a cellular telephone are provided that may include one or more surfaces coated with an antimicrobial treatment, which may include a silane quaternary ammonium salt and isopropyl alcohol. The silane quaternary ammonium salt may initially include an unreacted organofunctional silane that subsequently reacts with and covalently bonds to the surfaces of the touch screen, such as 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. Methods are also provided for coating, or otherwise integrating the antimicrobial treatment on or within a touch screen and a cellular telephone.

Abstract: The present invention relates to bath compositions that may release nitric oxide when combined with an aqueous solution, thereby producing a nitric oxide releasing soak and/or bath. The present invention also relates to methods of using nitric oxide releasing bath compositions.

Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

Abstract: Compounds, ceramide analogues, having a cyclic structure derived from cyclopropane, cyclobutane or cyclopentane, the ring bearing two chains consisting of an amide function. Each amide function is attached to the ring by the nitrogen atom of the function and carries a hydrocarbon chain derived from a fatty acid. The amide functions can be cis or trans relative to one another. Processes for the preparation of these novel compounds as well as pharmaceutical and/or cosmetic compositions containing them.

Abstract: Fluid compositions are disclosed containing a branched organopolysiloxane and a carrier fluid. The branched organopolysiloxane is obtainable by reacting an organohydrogencyclosiloxane and an alkenyl terminated polydiorganosiloxane. The disclosed fluid compositions possess pituitous rheological properties.